Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: A retrospective study

Journal of Dermatological Treatment

Volumn 25, Issue 1, 2014, Pages 73-74

  Di Lernia, Vito ^a   Ricci, Cinzia ^a   Lallas, Aimilios ^a   Ficarelli, Elena ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Adalimumab; Anti TNF; Etanercept; Infliximab; Non responders; Psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SMOKING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY MASS INDEX; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SMOKING; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890492966     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.800184     Document Type: Article

References (13)

1. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95-102.
2. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.
3. Matsumoto Y, Maeda T, Tsuboi R, Okubo Y. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: Report of two cases. J Dermatol. 2012;53:45-47.
4. Alsharqi A, Parslew R, Dever B, Arslanian V. Is there a benefit from using a subsequent anti-TNF a medication in psoriasis patients who failed their first or second anti-TNF a agent? Australas J Dermatol. 2012;53:e45-e47.
5. Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol. 2011;25:1012-1020.
6. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558-1565.
7. Söderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1-9.
8. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217:365-373.
9. Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat. 2012;23:404-409.
10. Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol. 2010; 6:957-966.
11. Ingegnoli F, Favalli EG, Meroni PL. Does polymorphism of genes coding for pro-inflammatory mediators predict the clinical response to TNF-alpha blocking agents? A review analysis of the literature. Autoimmun Rev. 2011;10:460-463.
12. Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J. 2013;doi: 10.1038/tpj.2012.53.
13. Jókai H, Szakonyi J, Kontár O, Barna G, Inotai D, Kárpáti S, Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNFalpha inhibitor biological therapy in psoriasis. Exp Dermatol. 2013;22: 221-223.